That's an improvement in OS of 13.8 months, or an increase of 58% longer than the Control group.
I am hoping that with the changes in the Phase 3 trial, the OS & PFS differences between the ICT-107 group and the Control group, will be even more dramatic & pronounced. The changes in the Phase 3 trial include:
1. More doses of ICT-107 for the treatment group.
2. Treat only HLA-A2+ patients only
3. Treat the control group with monocytes only, and not any dendritic cells